valsartan has been researched along with Death, Sudden, Cardiac in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (13.64) | 29.6817 |
| 2010's | 12 (54.55) | 24.3611 |
| 2020's | 7 (31.82) | 2.80 |
| Authors | Studies |
|---|---|
| Heidenreich, PA; Kohsaka, S; Lewis, EF; Sandhu, AT; Turakhia, MP | 1 |
| Bernard, ML; Dominic, P; Elise Hiltbold, A; Huang, E; Khatib, S; Morin, DP; Polin, GM; Rogers, PA | 1 |
| Ayesta, A; Datino, T; Díez-Villanueva, P; Esteban-Fernández, A; Jimenez-Mendez, C; Martínez-Sellés, M; Pérez, Á | 1 |
| Balsam, P; Dąbrowski, R; Farkowski, MM; Gackowski, A; Grabowski, M; Jędrzejczyk-Patej, E; Kalarus, Z; Leszek, P; Nessler, J; Opolski, G; Ozierański, K; Przybylski, A; Sterliński, M | 1 |
| Akin, I; Borggrefe, M; El-Battrawy, I | 1 |
| Al-Khatib, SM; Blumer, V; Felker, GM | 1 |
| Chatterjee, NA; Claggett, B; Desai, AS; Lefkowitz, M; McMurray, JJV; Packer, M; Rohde, LE; Rouleau, J; Shi, V; Solomon, SD; Swedberg, K; Vaduganathan, M; Zile, M | 1 |
| Ramakrishna, S; Salazar, JW; Tseng, ZH | 1 |
| Rohde, LE; Solomon, SD | 1 |
| Butler, J; DeFilippis, EM; Vaduganathan, M | 1 |
| Bayes-Genis, A; Sarrias, A | 1 |
| Ceyssens, W; Dupont, M; Luwel, E; Martens, P; Mullens, W; Nuyens, D; Rivero-Ayerza, M; Van Herendael, H; Vercammen, J | 1 |
| Kondo, T; Maeda, K; Matsushita, K; Muramatsu, T; Murohara, T; Nagahiro, T; Shintani, S; Yamashita, K | 1 |
| Califf, RM; Kober, L; Lewis, EF; Li, Y; Pfeffer, MA; Reed, SD; Rouleau, JL; Schulman, KA; Solomon, SD; Velazquez, EJ; Weinfurt, KP; White, HD | 1 |
| Alfonso Manterola, F; Almenar Bonet, L; Ariza Solé, A; Arribas Ynsaurriaga, F; Bover Freire, R; Bueno, H; Coca Payeras, A; Díaz Molina, B; Evangelista Masip, A; Ferreira González, I; González Juanatey, JR; Jiménez Navarro, M; Lambert Rodríguez, JL; López de Sá, E; López Fernández, S; Manito Lorite, N; Marin Ortuño, F; Martín Asenjo, R; Mirabet Pérez, S; Pascual Figal, D; Pérez de Isla, L; Rodríguez Padial, L; Ruilope Urioste, LM; San Román Calvar, JA; Sánchez Fernández, PL; Segovia Cubero, J; Sionis Green, A; Sionis, A; Varela Román, A; Vázquez García, R; Zamorano Gómez, JL | 1 |
| Böhm, M; Gong, J; Jhund, PS; Lefkowitz, MP; McMurray, JJV; Packer, M; Rizkala, AR; Rouleau, JL; Shi, VC; Solomon, SD; Swedberg, K; Young, R; Zile, MR | 1 |
| Al-Khatib, SM; Califf, RM; McMurray, JJ; Pfeffer, MA; Piccini, JP; Pieper, K; Solomon, SD; Van de Werf, F; Velazquez, EJ; Zhang, M | 1 |
| Bode, C; Braunwald, E; Cannon, CP; Lopez-Sendon, J; Lukashevich, V; Maboudian, M; McCabe, CH; Morrow, DA; Ogorek, M; Oude Ophuis, AJ; Rifai, N; Ruda, M; Ruzyllo, W; Scirica, BM; Swedberg, K | 1 |
| Liew, R | 1 |
| Cherubini, A; Di Lenarda, A; Perkan, A; Salvatore, L; Sinagra, G | 1 |
| Aknay, N; Carson, P; Chiang, YT; Cohn, JN; Farsang, C; Glazer, RD; Krum, H; Maggioni, AP | 1 |
| Abts, M; Kastrati, D; Schühlen, H | 1 |
4 review(s) available for valsartan and Death, Sudden, Cardiac
| Article | Year |
|---|---|
Sacubitril/valsartan: An antiarrhythmic drug?
Topics: Angiotensin Receptor Antagonists; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2022 |
Do Elderly Patients with Heart Failure and Reduced Ejection Fraction Benefit from Pharmacological Strategies for Prevention of Arrhythmic Events?
Topics: Aged; Angiotensin Receptor Antagonists; Arrhythmias, Cardiac; Biphenyl Compounds; Death, Sudden, Cardiac; Drug Combinations; Heart Failure; Humans; Prognosis; Stroke Volume; Tetrazoles; Valsartan | 2023 |
[Almanac 2011: Cardiac arrhythmias and pacing. Review of selected studies that have driven recent advances in clinical cardiology -- by the Editors of the Network Task Force of the European Society of Cardiology].
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Cardiac Resynchronization Therapy; Catheter Ablation; Clinical Trials as Topic; Death, Sudden, Cardiac; Defibrillators, Implantable; Evidence-Based Medicine; Humans; Quality of Life; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Tetrazoles; Thromboembolism; Treatment Outcome; Valine; Valsartan; Ventricular Fibrillation | 2012 |
[Treatment of heart failure: an update].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antidiuretic Hormone Receptor Antagonists; Antihypertensive Agents; Benzazepines; Bosentan; Carbazoles; Carvedilol; Death, Sudden, Cardiac; Defibrillators, Implantable; Double-Blind Method; Heart Failure; Heart-Assist Devices; Humans; Metoprolol; Multicenter Studies as Topic; Placebos; Propanolamines; Prospective Studies; Pyridines; Quality of Life; Randomized Controlled Trials as Topic; Sulfonamides; Tetrazoles; Valine; Valsartan; Vasodilator Agents | 2002 |
7 trial(s) available for valsartan and Death, Sudden, Cardiac
| Article | Year |
|---|---|
Effects of valsartan versus amlodipine in diabetic hypertensive patients with or without previous cardiovascular disease.
Topics: Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Case-Control Studies; Death, Sudden, Cardiac; Diabetes Mellitus, Type 2; Female; Heart Failure; Hospitalization; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Proportional Hazards Models; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction).
Topics: Acute Disease; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Bundle-Branch Block; Captopril; Death, Sudden, Cardiac; Drug Therapy, Combination; Female; Health Status; Heart Failure; Hospitalization; Humans; Male; Myocardial Infarction; Quality of Life; Recurrence; Stroke; Survivors; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2014 |
Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Blood Pressure; Chronic Disease; Death, Sudden, Cardiac; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Enalapril; Female; Heart Failure; Hospitalization; Humans; Hypotension; Male; Neprilysin; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2017 |
Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trial.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Captopril; Death, Sudden, Cardiac; Double-Blind Method; Female; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Recurrence; Risk Factors; Stroke Volume; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Dysfunction, Left | 2010 |
Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 Trial.
Topics: Acute Coronary Syndrome; Aged; Amides; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Female; Fumarates; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Natriuretic Peptide, Brain; Peptide Fragments; Renin; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2010 |
Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Death, Sudden, Cardiac; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heart Failure; Heart Rate; Humans; Male; Middle Aged; Quality of Life; Risk Factors; Single-Blind Method; Stroke Volume; Survival Analysis; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2004 |
[Intensive blood pressure reduction in patients with increased cardiovascular risk with high-dose combination therapy of 160 mg valsartan plus 25 mg hydrochlorothiazide. Results of the MACHT II observational study].
Topics: Antihypertensive Agents; Death, Sudden, Cardiac; Drug Administration Schedule; Drug Therapy, Combination; Female; Germany; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Risk Assessment; Risk Factors; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2007 |
11 other study(ies) available for valsartan and Death, Sudden, Cardiac
| Article | Year |
|---|---|
Evaluation of Quality of Care for US Veterans With Recent-Onset Heart Failure With Reduced Ejection Fraction.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Death, Sudden, Cardiac; Defibrillators, Implantable; Drug Combinations; Female; Guideline Adherence; Heart Failure; Humans; Hydralazine; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Mortality; Nitrates; Practice Guidelines as Topic; Quality of Health Care; Stroke Volume; United States; United States Department of Veterans Affairs; Valsartan; Veterans | 2022 |
The effect of sacubitril / valsartan on the occurrence of ventricular arrhythmia and the risk of sudden cardiac death in patients with chronic heart failure with reduced left ventricular ejection fraction. Expert opinion of the Heart Rhythm and Heart Fail
Topics: Aminobutyrates; Arrhythmias, Cardiac; Biphenyl Compounds; Cardiology; Death, Sudden, Cardiac; Drug Combinations; Female; Heart Failure; Humans; Male; Poland; Societies, Medical; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2019 |
The Risk for Sudden Cardiac Death and Effect of Treatment With Sacubitril/Valsartan in Heart Failure.
Topics: Aminobutyrates; Biphenyl Compounds; Death, Sudden, Cardiac; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2019 |
Medications Are Important for Sudden Cardiac Death Prevention But So Is the Implantable Cardioverter-Defibrillator.
Topics: Aminobutyrates; Biphenyl Compounds; Death, Sudden, Cardiac; Defibrillators, Implantable; Drug Combinations; Heart Failure; Humans; Tetrazoles; Valsartan | 2020 |
Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause: A PARADIGM-HF Analysis.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Death, Sudden, Cardiac; Defibrillators, Implantable; Drug Combinations; Heart Failure; Humans; North America; Prospective Studies; Stroke Volume; Tetrazoles; Valsartan | 2020 |
Presumed Sudden Cardiac Deaths in the PARADIGM-HF Trial.
Topics: Aminobutyrates; Biphenyl Compounds; Death, Sudden, Cardiac; Defibrillators, Implantable; Drug Combinations; Heart Failure; Humans; Valsartan | 2021 |
Reply: Presumed Sudden Cardiac Deaths in the PARADIGM-HF Trial.
Topics: Aminobutyrates; Biphenyl Compounds; Death, Sudden, Cardiac; Defibrillators, Implantable; Drug Combinations; Heart Failure; Humans; Valsartan | 2021 |
Waiting Period Before Implantable Cardioverter-Defibrillator Implantation in Newly Diagnosed Heart Failure With Reduced Ejection Fraction: A Window of Opportunity.
Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Clinical Decision-Making; Conservative Treatment; Death, Sudden, Cardiac; Defibrillators, Implantable; Drug Combinations; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Practice Guidelines as Topic; Stroke Volume; Tetrazoles; Time Factors; Time-to-Treatment; Valsartan; Ventricular Remodeling | 2017 |
Is Sacubitril/Valsartan (Also) an Antiarrhythmic Drug?
Topics: Aminobutyrates; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Biphenyl Compounds; Death, Sudden, Cardiac; Drug Combinations; Heart Failure; Heart Rate; Humans; Risk Factors; Tetrazoles; Treatment Outcome; Valsartan | 2018 |
Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Arrhythmias, Cardiac; Belgium; Biphenyl Compounds; Death, Sudden, Cardiac; Drug Combinations; Female; Follow-Up Studies; Heart Failure; Humans; Incidence; Male; Neprilysin; Retrospective Studies; Stroke Volume; Survival Rate; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2019 |
Comments on the 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure.
Topics: Acute Disease; Adrenergic beta-Antagonists; Algorithms; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Biphenyl Compounds; Cardiac Resynchronization Therapy; Cardiovascular Agents; Chronic Disease; Death, Sudden, Cardiac; Defibrillators, Implantable; Drug Combinations; Early Medical Intervention; Echocardiography; Europe; Extracorporeal Membrane Oxygenation; Heart Failure; Humans; Ivabradine; Mineralocorticoid Receptor Antagonists; Natriuretic Peptides; Practice Guidelines as Topic; Spain; Stroke Volume; Tetrazoles; Valsartan | 2016 |